SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-443967"
 

Sökning: id:"swepub:oai:DiVA.org:uu-443967" > Phase 1 study to ac...

Phase 1 study to access safety, tolerability, pharmacokinetics, and pharmacodynamics of kynurenine in healthy volunteers

Al-Mahdi Al-Karagholi, Mohammad (författare)
Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Glostrup, Denmark
Møller Hansen, Jakob (författare)
Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Glostrup, Denmark; Rigshosp Glostrup, Danish Knowledge Ctr Headache Disorders, Glostrup, Denmark
Abou-Kassem, Dalia (författare)
Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Glostrup, Denmark
visa fler...
Koldbro Hansted, Anna (författare)
Univ Copenhagen, Rigshosp Glostrup, Fac Hlth & Med Sci, Glostrup Res Inst,Danish Headache Ctr, Glostrup, Denmark
Ubhayasekera, Kumari (författare)
Uppsala universitet,Analytisk kemi
Bergquist, Jonas (författare)
Uppsala universitet,Analytisk kemi
Vécsei, László (författare)
Univ Szeged, Dept Neurol, Szeged, Hungary; Univ Szeged, MTA SZTE Neurosci Res Grp, Szeged, Hungary
Jansen-Olesen, Inger (författare)
Univ Copenhagen, Rigshosp Glostrup, Fac Hlth & Med Sci, Glostrup Res Inst, Danish Headache Ctr, Glostrup, Denmark
Ashina, Messoud (författare)
Univ Copenhagen, Danish Headache Ctr, Dept Neurol, Glostrup, Denmark; Rigshosp Glostrup, Danish Knowledge Ctr Headache Disorders, Glostrup, Denmark
visa färre...
 (creator_code:org_t)
2021-03-07
2021
Engelska.
Ingår i: Pharmacology Research & Perspectives. - : John Wiley & Sons. - 2052-1707. ; 9:2
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • The kynurenine pathway (KP) is the main path for tryptophan metabolism, and it represents a multitude of potential sites for drug discovery in neuroscience, including pain, stroke, and epilepsy. L-kynurenine (LKYN), the first active metabolite in the pathway, emerges to be a prodrug targeting glutamate receptors. The safety, tolerability, pharmacokinetics, and pharmacodynamics of LKYN in humans have not been previously investigated. In an open-label, single ascending dose study, six participants received an intravenous infusion of 50, 100, and 150 µg/kg LKYN and new six participants received an intravenous infusion of 0.3, 0.5, 1, and 5 mg/kg LKYN. To compare the pharmacological effects between species, we investigated in vivo the vascular effects of LKYN in rats. In humans, LKYN was safe and well-tolerated at all dose levels examined. After infusion, LKYN plasma concentration increased significantly over time 3.23 ± 1.12 µg/mL (after 50 µg/kg), 4.04 ± 1.1 µg/mL (after 100 µg/kg), and 5.25 ± 1.01 µg/mL (after 150 µg/kg) (p ≤ 0.001). We observed no vascular changes after infusion compared with baseline. In rats, LKYN had no effect on HR and MAP and caused no dilation of dural and pial arteries. This first-in-human study of LKYN showed that LKYN was safe and well-tolerated after intravenous infusion up to 5 mg/kg over 20 minutes. The lack of change in LKYN metabolites in plasma suggests a relatively slow metabolism of LKYN and no or little feed-back effect of LKYN on its synthesis. The therapeutic potential of LKYN in stroke and epilepsy should be explored in future studies in humans.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

epilepsy
glutamat
kynurenic acid
migraine
stroke

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy